Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burundi antimalarial efficacy study of artesunate + amodiaquine and artemether + lumefantrine
ACTRN12616001006437Phase 4Withdrawn
- Sponsor
- Ministry of Health of Burundi
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artesunate, amodiaquine, artemether and lumefantrine in malaria and Falciparum malaria (PF) (2 arms), sponsored by Ministry of Health of Burundi. Primary endpoints: Treatment failure rate, Adequate clinical and parasitological response and 1 more. Planned start Jul 2016; status: withdrawn.
02
Drugs
artesunateamodiaquineartemetherlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12616001006437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001006437.